Literature DB >> 24957697

Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease.

Jun-Bin Suh1, Seon Mee Kim, Geum-Ju Cho, Kyung Mook Choi.   

Abstract

OBJECTIVE: Adipocyte fatty acid-binding-protein (A-FABP), retinol-binding protein 4 (RBP4), and lipocalin-2 have been identified as adipokines that may link obesity, insulin resistance, and metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD) is regarded as a manifestation of metabolic syndrome. We evaluated the relationship of A-FABP, RBP4, and lipocalin-2 to variables related to metabolic syndrome and NAFLD.
METHODS: A total of 140 subjects (72 males and 68 females) were included in this study. Subjects were divided into two groups (NAFLD, n = 73 and normal, n = 67) based on the detection of a fatty liver by ultrasonography.
RESULTS: Serum A-FABP levels were higher in the NAFLD group than in the normal group (18.42 ± 7.24 ng/mL vs. 15.74 ± 7.02 ng/mL, p = 0.022). After adjusting for age and sex, we observed that body mass index (BMI), diastolic blood pressure, waist circumference, body fat percentage, triglycerides, and serum RBP4 levels were positively associated with serum A-FABP levels in all subjects. Multiple linear regression analysis revealed that systolic blood pressure, diastolic blood pressure, and serum RBP4 levels were independently associated with serum A-FABP levels. In logistic regression analysis, patients in the higher quartiles of A-FABP levels had higher odds ratios (OR) for the presence of NALFD than patients in the lower quartiles (OR: 3.56; 95% confident interval or CI: 1.25, 10.14).
CONCLUSIONS: We observed higher serum A-FABP levels in the NAFLD group than in the normal group. However, serum RBP4 and lipocalin-2 levels appeared to have different relationships with several variables related to metabolic syndrome and NAFLD, which contradict results of previous studies.

Entities:  

Keywords:  adipocyte fatty acid-binding protein; metabolic syndrome; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2014        PMID: 24957697     DOI: 10.3109/00365521.2013.836754

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Adipocytokines as Risk Factors for Development of Nonalcoholic Fatty Liver Disease in Children.

Authors:  Paweł Małecki; Anna Mania; Joanna Tracz; Magdalena Łuczak; Katarzyna Mazur-Melewska; Magdalena Figlerowicz
Journal:  J Clin Exp Hepatol       Date:  2021-03-10

2.  Circulating Adipocyte Fatty Acid Binding Protein (FABP4) Levels Are Associated with Irisin in the Middle-Aged General Chinese Population.

Authors:  Shan Zhang; Lili Yang; Peihong Chen; Hua Jin; Xinmiao Xie; Meili Yang; Ting Gao; Cheng Hu; Xuemei Yu
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

Review 3.  Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Zhongwei Zhou; Hongmei Chen; Huixiang Ju; Mingzhong Sun
Journal:  Lipids Health Dis       Date:  2017-09-20       Impact factor: 3.876

4.  FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis.

Authors:  Audrey Coilly; Christophe Desterke; Catherine Guettier; Didier Samuel; Franck Chiappini
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

5.  Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals.

Authors:  Marenao Tanaka; Satoko Takahashi; Yukimura Higashiura; Akiko Sakai; Masayuki Koyama; Shigeyuki Saitoh; Kazuaki Shimamoto; Hirofumi Ohnishi; Masato Furuhashi
Journal:  J Diabetes Investig       Date:  2022-01-03       Impact factor: 3.681

Review 6.  Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

Authors:  Vera Francisco; Maria Jesus Sanz; José T Real; Patrice Marques; Maurizio Capuozzo; Djedjiga Ait Eldjoudi; Oreste Gualillo
Journal:  Biology (Basel)       Date:  2022-08-19

7.  Chinese olive extract ameliorates hepatic lipid accumulation in vitro and in vivo by regulating lipid metabolism.

Authors:  Yu-Te Yeh; Yan-Yu Cho; Shu-Chen Hsieh; An-Na Chiang
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

8.  Urinary fatty acid and retinol binding protein-4 predict CKD progression in severe NAFLD patients with hypertension: 4-year study with clinical and experimental approaches.

Authors:  Yu-Lien Tsai; Chih-Wei Liu; Shiang-Fen Huang; Ying-Ying Yang; Ming-Wei Lin; Chia-Chang Huang; Tzu-Hao Li; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

Review 9.  Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.

Authors:  Juan Moreno-Vedia; Josefa Girona; Daiana Ibarretxe; Lluís Masana; Ricardo Rodríguez-Calvo
Journal:  Biomedicines       Date:  2022-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.